Nilocas

Nilocas is pioneering non-invasive coronary heart disease (CHD) detection technology aimed at transforming the diagnostic landscape for cardiovascular conditions. Operating primarily in the UK, with plans to expand into Europe and the USA, Nilocas targets patients who would otherwise undergo invasive and expensive diagnostic cardiac angiograms. The company's innovative device aims to identify CHD without the need for inserting stents or exposing patients to high levels of radiation, thereby significantly reducing healthcare costs and improving patient outcomes.

Nilocas collaborates with a broad ecosystem of academic and clinical network partners, public and private hospital organizations, industry associations, national innovation accelerators, and patient advocacy groups. The business model revolves around developing and commercializing this non-invasive diagnostic device, supported by seed investment and non-dilutive grant funding. Revenue is expected to be generated through device sales, licensing agreements, and potentially through partnerships with healthcare providers and insurers.

The company is currently preparing for its first human viability trial at Barts Heart Centre, following significant funding from NLC and Queen Mary University London. This trial is a critical step towards validating the device's efficacy and safety, paving the way for broader clinical adoption.

Keywords: Non-invasive, coronary heart disease, diagnostic device, healthcare innovation, cost-saving, early detection, clinical trials, cardiovascular, medical technology, patient outcomes.